Biotech Startups

Promega provides a portfolio of reporter bioassays used to characterize and develop monoclonal antibody and cell-based therapeutics for drug developers. The assays measure biological functions including Fc effector activity, immune checkpoint modulation, T cell activation, and cytokine signaling.

1 investor

Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.

1 investor

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.

1 investor

ProNovo Therapeutics is a biotechnology company developing precision small-molecule therapeutics for neuropsychiatric disorders, including Major Depressive Disorder and Schizophrenia. The company applies a precision-medicine approach based on genetic susceptibility, disease pathophysiology, and biomarkers to advance preclinical drug programs toward clinical development.

1 investor

Propeller Bio discovers and develops biologic therapeutics that target multiple disease-driving pathways to achieve synergistic effects, aimed at patients with unmet medical needs. The company operates in the drug discovery and development space and is based in the Bay Area, California.

1 investor

ProPharma provides outsourced clinical, regulatory, and quality staffing solutions for pharmaceutical and biotech companies through a flexible staffing partnership (FSP) model. The company supplies experienced professionals from a global network to support drug development and compliance-related functions.

1 investor

PROSION Therapeutics develops platform technology for oncology and other diseases based on research into protein targets like Ena/VASP; the company translates academic research into clinical treatments for conditions with significant patient impact.

1 investor

Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases. The company leverages its proprietary technology platform and extensive expertise in drug development, regulatory affairs, and pharmaceutical manufacturing.

1 investor

Protara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.

1 investor

Protedyne develops laboratory automation platforms for pharmaceutical, biotech, and diagnostic testing companies to handle high-volume testing with rapid turnaround times. The company applies industrial automation design principles to laboratory equipment serving clinical and research environments.

1 investor

ProteomEdge develops mass spectrometry-based analytical platforms and proprietary heavy-labelled protein standard panels for absolute protein quantification in blood plasma, targeting clinically relevant biomarkers such as apolipoproteins, complement factors, and liver disease markers. Its products serve research and translational proteomics customers, including academic core facilities and precision medicine researchers. Based in Stockholm, Sweden.

1 investor

Protera builds functional protein ingredients for the food industry using its madi platform, which combines generative AI and computational biology to design novel proteins produced through precision fermentation. Its applications range from food products to advanced materials.

1 investor

Proteros provides structural biology, cryo-EM, protein sciences, and biophysics research services for drug discovery and development. The company operates cutting-edge laboratory facilities in the Munich biotech cluster in Germany.

1 investor

Proterro uses a patented technology platform to convert captured waste CO2 into high-value products across two categories, Proterro Sugars and Proterro Nutritionals. It works with partners to develop custom molecules and products tailored to their specifications, purity standards, and supply requirements.

1 investor

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.

1 investor

ProThera Biologics develops therapies based on Inter-alpha inhibitor proteins (IAIP), a class of human plasma proteins with anti-inflammatory activity, to treat patients with severe inflammatory diseases. The company targets life-threatening immune responses associated with high mortality in intensive care settings.

1 investor

Protiva develops nature-derived pigments engineered for industrial use, offering traceable, certified colorants validated to work within existing manufacturing processes without hazardous chemistry. The company targets industry as a sustainable alternative in the materials and colorants sector.

1 investor

Protomer develops dynamic medicines that modify their activity in the body to increase potency where and when needed. Founded by Caltech alumni and faculty, the company was acquired by Eli Lilly in 2021 and operates as a biotech subsidiary.

1 investor

ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.

1 investor

Protyon develops personalized cancer therapies using computational modeling expertise. The company serves cancer patients and researchers in the biotech and healthcare industry.

1 investor

Provasctec develops a cell therapy combining mesenchymal stem cells with a biodegradable delivery device to create new vascular pathways, with a lead program targeting critical limb ischemia in peripheral artery disease patients. The company operates in regenerative medicine, applying biomaterial engineering and precision cell delivery to conditions including inflammation, cancer, and age-related diseases.

1 investor

Proveca is a pharmaceutical company that develops and licenses age-appropriate, licensed medicines for children, focusing on paediatric unmet medical needs. Its current therapy areas are neurology and cardiology, targeting children with chronic conditions requiring long-term treatment.

1 investor

Sanofi is a pharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally. The company operates in over 100 countries with a focus on breakthrough science and healthcare innovation.

1 investor

Provepharm is a pharmaceutical company specializing in health-related dyes and colorants, committed to sustainable development and providing quality information on health products to medical professionals. The company operates internationally with French R&D expertise and is a UN Global Compact member.

1 investor